Pharmaceutical group

SERB

41 medicines5 countries

A group of 4 companies with 41 medicines in 5 countries.

Its medicines

Group structure

4 companies in 2 countries

France2

Netherlands1

SerbAuthorisation holder

Headquarters not stated1

Serb SaAuthorisation holder · 23 medicines · listed in Canada, Spain +4

Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.

Medicines

Every medicine of every company in the group, current ones first.

1–25 of 41

Medicine	Substance	Country	Status	Authorised
AMIFAMPRIDINA SERBCompressa	Amifampridine	Italy	Authorised
Amifampridine SERB	Amifampridine	EU (EMA)	Authorised	2022
Amifampridine SERB 10 mg, tablettenTablet	Amifampridine	Netherlands	Authorised	2022
AMVERSIOPolvere orale	Betaine	Italy	Authorised
Amversio	Betaine	EU (EMA)	Authorised	2022
AMVERSIO 1 G POLVO ORAL EFG1 g · Polvo oral	Betaine	Spain	Marketed	2024
Amversio 1g, poeder voor oraal gebruikPoeder voor oraal gebruik	Betaine	Netherlands	Authorised	2022
CONTRATHIONPolvere e solvente per soluzione per infusione endovenosa	Pralidoxime	Italy	Authorised
Cyanokit	Hydroxocobalamin	EU (EMA)	Authorised	2007
CYANOKITPolvere per soluzione per infusione endovenosa	Hydroxocobalamin	Italy	Authorised
CYANOKIT5 g / vial · Powder For Solution	Hydroxocobalamin	Canada	Marketed	2012
Cyanokit 2,5 g, poeder voor oplossing voor infusiePoeder voor oplossing voor infusie	Hydroxocobalamin	Netherlands	Authorised	2007
CYANOKIT 2,5 g POLVO PARA SOLUCION PARA PERFUSION2,5 g · Polvo para solución para perfusión	Hydroxocobalamin	Spain	Authorised	2008
Cyanokit 5 g, poeder voor oplossing voor infusiePoeder voor oplossing voor infusie	Hydroxocobalamin	Netherlands	Authorised	2010
CYANOKIT 5 g POLVO PARA SOLUCION PARA PERFUSION5 g · Polvo para solución para perfusión	Hydroxocobalamin	Spain	Marketed	2010
EFFORTILGocce orali, soluzione	Etilefrina	Italy	Authorised
EPISTATUSSoluzione per mucosa orale	Midazolam	Italy	Authorised
FIRDAPSECompressa	Amifampridine	Italy	Authorised
FIRDAPSE 10 MG COMPRIMIDOS10 mg · Comprimido	Amifampridine	Spain	Authorised	2015
Firdapse 10 mg, tablettenTablet	Amifampridine	Netherlands	Authorised	2009
Firdapse (previously Zenas)	Amifampridine	EU (EMA)	Authorised	2009
FLUORESCEINA OCULOS 10% SOLUCION INYECTABLE500 mg · Solución inyectable	Fluorescein	Spain	Marketed	2003
Fomepizole SERB 5 mg/ml, concentraat voor oplossing voor infusieConcentraat voor oplossing voor infusie	Fomepizole	Netherlands	Authorised	2002
Garacol 130 mgImplantaat	Gentamicin	Netherlands	Authorised	1995
Garacol 32,5 mgImplantaat	Gentamicin	Netherlands	Authorised	1997

Sources and licences

Country	Medicines	Current	Companies
Netherlands	15	15	Companies All medicines
Italy	10	10	Companies All medicines
Spain	8	8	Companies All medicines
European Union (EMA)	6	6	Companies All medicines
Canada	2	2	Companies All medicines

Compiled by Prognia from the public medicine and company registers below. Logos are not used.

Companies are grouped by Prognia from the names regulators publish; not an official corporate structure.

European Medicines Agency

Source: European Medicines Agency (EPAR data).

Licence: EMA reuse policy (source acknowledgement required)

Agencia Española de Medicamentos y Productos Sanitarios (CIMA)

Fuente de la información: AEMPS (CIMA).

Licence: AEMPS open data reuse with attribution

Base de données publique des médicaments (ANSM, HAS, UNCAM)

Source: BDPM (ANSM, HAS, UNCAM).

Licence: Licence Ouverte v1.0

Health Canada, Canada

Health Canada, Drug Product Database, company API, entire response observed 2026-10-10T15:12:05.508784+00:00; native facts projected by Prognia.

Licence: Open Government Licence Canada

Health Canada, Canada

Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.

Licence: Open Government Licence Canada

Agencia Española de Medicamentos y Productos Sanitarios

Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA presentaciones, acquired 11 October 2026 UTC; each source response/update date retained.

Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required

All 15 sources

Agencia Española de Medicamentos y Productos Sanitarios

Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.

Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required

BDPM / ANSM, HAS and UNCAM

BDPM / ANSM, HAS and UNCAM; original URLs and each update date retained

Licence: BDPM exact Licence Ouverte v1.0 (October 2011)

INSEE via DINUM API Recherche d’entreprises

INSEE (www.insee.fr), via DINUM API Recherche d’entreprises; include original record update date and retrieval date

Licence: Licence Ouverte / Open Licence

Medicines and Healthcare products Regulatory Agency (MHRA), United Kingdom

Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; Category 1 list; publication updated 25 August 2026; acquired 2026-10-15T08:18:47.757811+00:00; original workbook cells and factual authorization/holder projections adapted under Open Government Licence v3.0.

Medicines and Healthcare products Regulatory Agency (MHRA), United Kingdom

Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; Category 2 list; publication updated 25 August 2026; acquired 2026-10-15T08:18:48.423930+00:00; original workbook cells and factual authorization/holder projections adapted under Open Government Licence v3.0.

Agenzia Italiana del Farmaco (AIFA), Italy

Agenzia Italiana del Farmaco (AIFA); https://www.aifa.gov.it/documents/20142/3815901/Classe_A_per_principio_attivo_31-05-2026.csv; HTTP Last-Modified Mon, 28 Sep 2026 08:46:41 GMT; acquired 2026-10-13T17:21:06.055244+00:00; native fields retained, source identifier and role projections are adaptations.

Licence: CC BY 4.0; AIFA published open-data catalog

Agenzia Italiana del Farmaco (AIFA), Italy

Agenzia Italiana del Farmaco (AIFA); https://www.aifa.gov.it/documents/20142/3815901/Classe_H_per_principio_attivo_31-05-2026.csv; HTTP Last-Modified Mon, 28 Sep 2026 08:46:40 GMT; acquired 2026-10-13T17:21:06.034935+00:00; native fields retained, source identifier and role projections are adaptations.

Licence: CC BY 4.0; AIFA published open-data catalog

Agenzia Italiana del Farmaco (AIFA), Italy

Agenzia Italiana del Farmaco (AIFA); https://drive.aifa.gov.it/farmaci/confezioni_fornitura.csv; HTTP Last-Modified Mon, 12 Oct 2026 23:02:44 GMT; acquired 2026-10-13T17:21:16.224007+00:00; native fields retained, source identifier and role projections are adaptations.

Licence: CC BY 4.0; AIFA published open-data catalog

College ter Beoordeling van Geneesmiddelen

College ter Beoordeling van Geneesmiddelen, Geneesmiddeleninformatiebank metadata, source update 07-10-2026; downloaded 08-10-2026; factual adaptation.

Licence: Conditional noncreative administrative factual metadata; no dataset-wide CC0 claim

Report an error or request removalCorrections from the company itself are welcome.

SERB

Group structure

France2

Netherlands1

Headquarters not stated1

Medicines

Know your medicines, with the sources.

Countries

Therapeutic areas

Top substances

Sources and licences

At a glance

Group structure

🇫🇷France2

🇳🇱Netherlands1

Headquarters not stated1

Medicines

Know your medicines, with the sources.

Countries

Therapeutic areas

Top substances

Sources and licences

At a glance

France2

Netherlands1